Evidence map›Paper›PMID 31245501›Full record

ArticleRegenerative therapy2016

Application of cell growth analysis to the quality assessment of human cell-processed therapeutic products as a testing method for immortalized cellular impurities.

Nozomi Hasebe-Takada, Ken Kono, Satoshi Yasuda, Rumi Sawada, Akifumi Matsuyama, Yoji Sato

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nozomi Hasebe-TakadaDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Ken KonoDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Satoshi YasudaDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Rumi SawadaDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Akifumi MatsuyamaPlatform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health and Nutrition, Amagasaki, Japan.
Yoji SatoDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
National Institute of Health Sciences · JPNational Institute of Biomedical Innovation, Health and Nutrition · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In human cell-processed therapeutic products (hCTPs) for clinical application, tumorigenic cellular impurities in the manufacturing process are a major concern. Because cellular immortalization is one of the prerequisite steps in tumorigenesis, we tested whether cell growth analysis can be employed to check for immortalized (and potentially tumorigenic) cellular impurities in hCTPs. We monitored the growth of human bone marrow-derived mesenchymal stem cells (BMSCs) mixed with HeLa cells at a ratio of 1/10

Indexed as

Adipose-derived stem cellADSC, adipose-derived stem cellBMSC, bone marrow-derived mesenchymal stem cellBone marrow-derived mesenchymal stem cellCellular therapyDMEM, Dulbecco's modified Eagle's mediumFBS, fetal bovine serumhCTP, human cell-processed therapeutic producthMSC, human mesenchymal stem cellhTERT, human telomerase reverse transcriptasePBS, phosphate buffered salineP = n, passage nqRT-PCR, quantitative reverse transcription polymerase chain reactionQuality assessmentRegenerative medicineTumorigenicity

Identifiers

PMID31245501
PMCPMC6581850
OpenAlexW2513644758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.